MedTrace Logo

Caffeine Supplementation, Resistance Training and Blood Antioxidant Status

NCT05230303 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-03-10

No results posted yet for this study

Summary

The purpose of this study is to verify the effect of acute caffeine intake on resistance training volume and blood antioxidant status, in a randomised, double-blind, placebo-controlled crossover trial.

Conditions

  • Caffeine

Interventions

DIETARY_SUPPLEMENT

Caffeine supplementation

Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.

DIETARY_SUPPLEMENT

Placebo treatment

The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.

Sponsors & Collaborators

  • The Jerzy Kukuczka Academy of Physical Education in Katowice

    lead OTHER

Principal Investigators

  • Adam Zając, Profesor · The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05230303 on ClinicalTrials.gov